6th Annual Oncolytic Virotherapy Summit
26-28 Oct 2021
Eurofins Viracor BioPharma will be exhibiting and sponsoring the 6th Annual Oncolytic Virotherapy Summit in Boston, October 26-28th, and we are excited to share our latest comprehensive assay offering for next generation sequencing to enable genomic profiling of tumor samples with PanCancerIQ™. Kristen Mickey will be presenting on October 28th "Viral shedding and infectivity testing in clinical trials of oncolytic virotherapies".
Eurofins Viracor BioPharma Immunotherapy Force Multiplier
It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.